136 related articles for article (PubMed ID: 33127094)
1. Evaluating the risk of re-recurrence in patients with persistent/recurrent thyroid carcinoma after initial reoperation.
Xu S; Li Q; Wang Z; Huang H; Wang X; Liu S; Liu J
Surgery; 2021 Apr; 169(4):837-843. PubMed ID: 33127094
[TBL] [Abstract][Full Text] [Related]
2. The outcomes of first reoperation for locoregionally recurrent/persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation.
Yim JH; Kim WB; Kim EY; Kim WG; Kim TY; Ryu JS; Gong G; Hong SJ; Shong YK
J Clin Endocrinol Metab; 2011 Jul; 96(7):2049-56. PubMed ID: 21508143
[TBL] [Abstract][Full Text] [Related]
3. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors for Re-recurrence After First Reoperative Surgery for Locoregional Recurrent/Persistent Papillary Thyroid Carcinoma.
Lee HS; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
World J Surg; 2015 Aug; 39(8):1943-50. PubMed ID: 25820911
[TBL] [Abstract][Full Text] [Related]
5. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
[TBL] [Abstract][Full Text] [Related]
6. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.
Tuttle RM; Tala H; Shah J; Leboeuf R; Ghossein R; Gonen M; Brokhin M; Omry G; Fagin JA; Shaha A
Thyroid; 2010 Dec; 20(12):1341-9. PubMed ID: 21034228
[TBL] [Abstract][Full Text] [Related]
7. Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy.
Llamas-Olier AE; Cuéllar DI; Buitrago G
Thyroid; 2018 Oct; 28(10):1311-1317. PubMed ID: 30105948
[TBL] [Abstract][Full Text] [Related]
8. Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors.
Lamartina L; Borget I; Mirghani H; Al Ghuzlan A; Berdelou A; Bidault F; Deandreis D; Baudin E; Travagli JP; Schlumberger M; Hartl DM; Leboulleux S
J Clin Endocrinol Metab; 2017 Mar; 102(3):1020-1031. PubMed ID: 28359102
[TBL] [Abstract][Full Text] [Related]
9. Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.
Hung ML; Wu JX; Li N; Livhits MJ; Yeh MW
JAMA Surg; 2018 Dec; 153(12):1098-1104. PubMed ID: 30140908
[TBL] [Abstract][Full Text] [Related]
10. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
11. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Efficacy of Lymph Node Reoperation for Persistent Papillary Thyroid Cancer: 13-Year Follow-Up.
Onuma AE; Beal EW; Nabhan F; Hughes T; Farrar WB; Phay J; Ringel MD; Kloos RT; Shirley LA
Ann Surg Oncol; 2019 Jun; 26(6):1737-1743. PubMed ID: 30820785
[TBL] [Abstract][Full Text] [Related]
13. Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: Predictive factors and operative management.
Chéreau N; Buffet C; Trésallet C; Tissier F; Leenhardt L; Menegaux F
Surgery; 2016 Mar; 159(3):755-62. PubMed ID: 26435440
[TBL] [Abstract][Full Text] [Related]
14. Recurrence following hemithyroidectomy in patients with low- and intermediate-risk papillary thyroid carcinoma.
Ahn D; Lee GJ; Sohn JH
Br J Surg; 2020 May; 107(6):687-694. PubMed ID: 32026467
[TBL] [Abstract][Full Text] [Related]
15. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
[No Abstract] [Full Text] [Related]
17. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response.
Vaisman F; Tala H; Grewal R; Tuttle RM
Thyroid; 2011 Dec; 21(12):1317-22. PubMed ID: 22136267
[TBL] [Abstract][Full Text] [Related]
18. Risk-adapted management of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients?
Ebina A; Sugitani I; Fujimoto Y; Yamada K
Surgery; 2014 Dec; 156(6):1579-88; discussion 1588-9. PubMed ID: 25262223
[TBL] [Abstract][Full Text] [Related]
19. Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma.
Kim Y; Roh JL; Song D; Cho KJ; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2020 Oct; 122(5):906-913. PubMed ID: 32588461
[TBL] [Abstract][Full Text] [Related]
20. Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.
Pitoia F; Abelleira E; Cross G
Endocrine; 2017 Jan; 55(1):200-208. PubMed ID: 27655291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
